Interaction Between Aging Defense Systems and the Start of Autoimmune Disease

One of the most extensively characterized hallmarks of aging is the gradual establishment of a chronic, low-grade inflammatory state often referred to as inflammaging (50). Unlike the acute, tightly regulated inflammatory responses that are essential for pathogen clearance and tissue repair, inflammaging is characterized by persistent elevations of pro-inflammatory mediators such as interleukin-6, tumor necrosis factor-alpha, and C-reactive protein (51, 52). This chronic inflammatory environment undermines resilience by exhausting immune regulatory networks, disrupting tissue repair capacity, and amplifying oxidative stress. In the context of autoimmunity, the same inflammatory mediators that impair resilience also serve as potent drivers of autoreactivity. The NLRP3 inflammasome, for example, represents a critical node at which resilience and autoimmunity converge (53). The NLRP3 (NOD-, LRR-, and pyrin domain-containing protein 3) inflammasome is a multiprotein sensor complex expressed predominantly in myeloid-lineage cells such as monocytes, macrophages, and dendritic cells, with lower but functionally relevant expression also found in endothelial, epithelial, and certain lymphoid cells (54 –57). As a cytosolic pattern-recognition receptor, NLRP3 detects diverse pathogen- and damage-associated molecular patterns, including extracellular ATP, crystalline particulates, and mitochondrial stress signals (58, 59). Upon activation, NLRP3 nucleates the inflammasome complex with ASC and caspase-1, leading to the maturation and secretion of interleukin-1β and interleukin-18 and, in some contexts, to pyroptotic cell death (60 –62). Through these mechanisms, NLRP3 functions as a central hub linking innate immune sensing, sterile inflammation, and tissue homeostasis (50, 51, 63 –65). Persistent or dysregulated activation of this inflammasome with age results in excessive interleukin-1β and interleukin-18 production, accelerating tissue degeneration and promoting differentiation of autoreactive T-helper subsets (66 –68). Thus, NLRP3 exemplifies the point at which resilience pathways and autoimmune activation converge within the broader landscape of inflammaging.

While activation of NLRP3 is necessary for host defense and tissue recovery, persistent activation with age results in excessive production of interleukin-1β and interleukin-18, which not only accelerate tissue degeneration but also promote differentiation of autoreactive T helper cell subsets (63, 69). Thus, inflammaging exemplifies a double-edged process in which the very molecules designed to sustain resilience under stress become catalysts for autoimmune activation when regulation fails.

Another prominent feature of aging is the accumulation of senescent cells within both immune and stromal compartments (70 –73). Senescence serves as an initially protective mechanism that prevents uncontrolled proliferation of damaged or stressed cells (74). However, when senescent cells persist, they adopt a senescence-associated secretory phenotype characterized by the release of pro-inflammatory cytokines, chemokines, growth factors, and matrix-degrading enzymes (75). For example, senescent fibroblasts in synovial tissue of patients with rheumatoid arthritis secrete interleukin-6 (IL-6), interleukin-8 (IL-8), and matrix metalloproteinases (MMPs), sustaining inflammation, recruiting immune cells, and contributing to joint destruction (34, 76) This secretory profile undermines resilience by impairing tissue architecture, promoting chronic inflammation, and disrupting regenerative niches. At the same time, the senescence-associated secretory phenotype facilitates autoimmune pathology by increasing the presentation of neo-antigens, enhancing autoreactive lymphocyte recruitment, and diminishing the clearance of self-reactive clones (76). Moreover, the age-associated decline in immune surveillance impairs the removal of senescent cells, further amplifying this cycle (77). The resulting environment simultaneously weakens the organism's capacity for adaptation and repair while priming the immune system for self-directed attack.

To fully understand how senescence influences resilience and autoimmune activation, it is essential to consider not only stromal cell senescence but also the senescence of immune populations (78, 79). Immune cells exhibit characteristic age-associated alterations that parallel those seen in stromal tissues, including impaired proliferative capacity, reduced receptor repertoire diversity, disrupted metabolic adaptability, and increased secretion of pro-inflammatory mediators (78, 80, 81). These senescent immune populations frequently develop a secretory profile analogous SASP, thereby reinforcing chronic inflammatory signaling and weakening the regulatory mechanisms that normally sustain immune tolerance (82, 83). In addition, senescent T cells, B cells, natural killer cells, and myeloid subsets demonstrate diminished ability to re-establish functional homeostasis following antigenic or inflammatory stimulation, which reflects a measurable decline in immune-system resilience (81, 84). This reduced capacity for recovery permits autoreactive lymphocytes that would ordinarily be suppressed or eliminated to persist within the immune repertoire (85). Incorporating immunosenescence into the conceptual framework of resilience therefore emphasizes that age-related functional decline occurs concurrently across both stromal and immune compartments, and that the interaction of these processes plays a central role in determining susceptibility to autoimmune activation.

Epigenetic integrity is a cornerstone of biological resilience, ensuring that transcriptional programs remain stable in the face of environmental and metabolic stressors (86, 87). With aging, however, there is progressive epigenetic dysregulation in DNA methylation, histone modifications, and non-coding RNA networks (88 –93). These changes destabilize resilience by eroding transcriptional fidelity, compromising lineage identity, and reducing the adaptability of immune and stromal cells (94 –96). The same epigenetic dysregulation also precipitates autoimmunity (33, 97). For example, hypomethylation at promoters of pro-inflammatory genes results in their aberrant expression in autoreactive T cells (98 –100). MicroRNAs such as miR-21 are frequently upregulated in aging and autoimmune contexts, where they suppress DNA methyltransferase activity, leading to global DNA hypomethylation and derepression of inflammatory genes (101 –103). Conversely, protective non-coding RNAs such as the long non-coding RNA GAS5 are often depleted, which removes critical checkpoints on T cell activation and immune tolerance (104 –106). These examples highlight how loss of epigenetic resilience not only destabilizes transcriptional regulation but directly enables autoimmune phenotypes (107 –109).

Metabolic homeostasis is increasingly recognized as a fundamental determinant of resilience in aging (110). Efficient energy production, redox balance, and nutrient sensing allow cells to withstand stress and recover from injury (111, 112). With age, mitochondrial dysfunction, accumulation of oxidative damage, and depletion of nicotinamide adenine dinucleotide undermine these processes, thereby weakening resilience (113 –115). Impaired autophagy further exacerbates this decline by allowing the buildup of damaged proteins and organelles that perpetuate cellular stress (116 –119). In immune cells, these metabolic defects have direct consequences for autoimmunity (120, 121). Mitochondrial dysfunction skews T cell differentiation toward pro-inflammatory phenotypes, while reduced nicotinamide adenine dinucleotide availability impairs the activity of sirtuins that normally suppress inflammatory transcriptional programs (122). At the same time, defective autophagy allows persistence of damaged self-antigens that can serve as triggers for autoreactive immune responses (123, 124). For example, in type 1 diabetes, impaired autophagy in pancreatic β cells leads to accumulation of damaged mitochondria and misfolded proteins that enhance β-cell immunogenicity, promoting T cell–mediated autoimmune destruction of islets (125, 126). Collectively, these metabolic failures diminish the ability of the organism to adapt to stress while simultaneously sustaining the survival and expansion of autoreactive lymphocytes.

Taken together, these overlapping pathways illustrate that the molecular mechanisms governing resilience in aging and those driving autoimmune susceptibility are not independent but rather deeply interconnected. Inflammation, senescence, epigenetic drift, and metabolic dysfunction each undermine the capacity to maintain equilibrium, and in doing so, they open the door to autoreactive immune responses. Recognizing this convergence provides a critical framework for rethinking both the biology of aging and the origins of autoimmune disease.

B cells play a central role in the pathogenesis of many autoimmune diseases through the production of autoantibodies, antigen presentation, and cytokine secretion (127 –130). The generation of autoreactive B cell clones reflects both defective central tolerance in the bone marrow and impaired peripheral checkpoints that normally eliminate or silence self-reactive cells (131, 132). With advancing age, several resilience-associated processes such as altered germinal center dynamics, reduced regulatory B cell function, and chronic inflammatory signaling can disrupt B cell homeostasis and favor autoantibody production (133 –135). However, while B cell dysregulation is a hallmark of autoimmune pathology, its contribution to resilience decline may be largely secondary to upstream failures in immune regulation, metabolic balance, and inflammatory control that create permissive conditions for autoreactive clones to persist. Consequently, in this perspective, B cell involvement is acknowledged as a downstream manifestation of resilience erosion rather than a primary driver of its decline. If certain autoimmune conditions are predominantly mediated by autoantibodies, such as lupus or myasthenia gravis, these may represent disease subsets in which resilience collapse amplifies rather than initiates humoral autoreactivity.

T cells constitute the central regulatory axis of adaptive immunity and are critical determinants of immune tolerance and resilience. Thymic selection, peripheral regulatory circuitry, and the metabolic and epigenetic programs that sustain T cell homeostasis collectively establish the capacity of the system to prevent autoreactivity (136). Aging perturbs each of these domains. Progressive thymic involution contracts the naïve T cell pool and reduces TCR repertoire diversity, limiting the organism's ability to replace dysfunctional or autoreactive clones (137). Concurrently, age-associated epigenetic drift destabilizes transcriptional networks that maintain quiescence and lineage fidelity, predisposing CD4⁺ and CD8⁺ T cells to aberrant activation (138). Mitochondrial dysfunction and impaired redox balance further bias differentiation toward pro-inflammatory Th1 and Th17 phenotypes while compromising the stability and suppressive capacity of regulatory T cells (139 –141). In parallel, the accumulation of senescent and terminally differentiated T cell subsets, marked by reduced proliferative potential and a pro-inflammatory secretory profile, diminishes the ability of system to resolve immune perturbations and restore equilibrium after stress (47).

Collectively, these alterations represent a progressive erosion of T cell–intrinsic resilience mechanisms that ordinarily buffer against transient antigenic or inflammatory insults. Their decline increases the persistence, survival, and effector potential of autoreactive T cells, thereby lowering the threshold for autoimmune activation. Integrating these processes into our framework reinforces the central thesis that late-onset autoimmunity reflects not an isolated failure of tolerance but the cumulative breakdown of resilience pathways that regulate T cell generation, maintenance, and functional recalibration across the lifespan.

Biological resilience serves as an integrative defense mechanism that protects the organism from the consequences of immune dysregulation (142 –144). In youth and early adulthood, robust resilience pathways compensate for molecular insults, limit the consequences of inflammatory bursts, and rapidly restore immune tolerance after perturbations (145, 146). For example, transient autoreactive responses that arise after infection are typically neutralized by the coordinated actions of regulatory T cells, tolerogenic dendritic cells, and efficient DNA repair and epigenetic stability (147 –150). With aging, however, these buffering systems decline (146, 151). The reduced capacity to resolve inflammation, the accumulation of senescent immune and stromal cells, and the diminished ability to reset epigenetic programs after stress all weaken this protective barrier (145, 152, 153). As a result, autoreactive immune cells that would normally be suppressed or eliminated may persist, gradually eroding immune tolerance and predisposing the individual to autoimmune pathology (109, 154 –156).

The decline of resilience does not occur in isolated domains but rather through a web of reinforcing feedback loops that accelerate the transition from adaptation to pathology (157 –159). Chronic low-grade inflammation, characteristic of inflammaging, is a prime example (20, 160 –162). Persistent inflammatory signaling not only erodes resilience by damaging tissues and exhausting regulatory immune pathways, but it also drives epigenetic drift (163 –165). Aberrant DNA methylation and histone modifications induced by inflammatory cytokines destabilize transcriptional programs that normally maintain immune quiescence (166 –168). This in turn promotes clonal expansion of autoreactive T and B cells, which perpetuate further inflammation, thereby completing a vicious cycle (169 –171). Metabolic dysfunction integrates into this loop by reducing mitochondrial fitness and impairing autophagy, thereby increasing the load of damaged self-antigens that amplify autoreactive responses (125, 126, 172). Each of these processes feeds forward into the others, creating a system in which resilience pathways are progressively dismantled and the probability of autoimmune onset is markedly increased (33, 169, 173).

Recent evidence highlights that resilience erosion and autoimmune activation manifest through tissue-specific vulnerabilities rather than uniform systemic decline. For example, in the pancreas, impaired β-cell autophagy and limited regenerative capacity heighten susceptibility to T-cell–mediated destruction, as seen in type 1 diabetes (174, 175). Certain organs appear more vulnerable because their intrinsic resilience reserves are relatively limited or because they are disproportionately affected by age-associated stressors (176). The pancreas is a prime example, as the autoimmune destruction of insulin-producing beta cells in type 1 diabetes highlights the inability of this tissue to regenerate once tolerance mechanisms are breached. In the central nervous system, age-related microglial senescence and mitochondrial dysfunction reduce metabolic flexibility and promote chronic neuroinflammation, contributing to autoimmune demyelination in diseases such as multiple sclerosis (177). Joints and connective tissues illustrate another paradigm, where persistent biomechanical stress synergizes with senescent fibroblast accumulation and inflammatory signaling to sustain rheumatoid arthritis pathology (178, 179). Multi-organ aging studies reveal that the rate and pattern of resilience loss differ across tissues, with metabolic and immune organs showing the earliest and most pronounced signatures of decline.

At the systems level, these localized changes are interconnected through inflammatory, metabolic, and epigenetic feedback loops that propagate stress signals across organ systems (180 –184). Declining mitochondrial function in immune cells, for instance, amplifies systemic cytokine production, which in turn accelerates senescence and impairs repair mechanisms in distal tissues (180, 185, 186). This bidirectional communication transforms resilience loss in one tissue into a whole-organism vulnerability, establishing a self-reinforcing cycle that culminates in widespread immune dysregulation and autoimmune pathology.

A pressing need is the development of reliable biomarkers that capture the shared biological space between resilience decline and autoimmune onset (Supplementary Table 1). Current tools such as epigenetic clocks (187 –189), which measure age-associated DNA methylation drift, provide insights into biological age but rarely incorporate immune-specific information. Future efforts should focus on composite biomarker signatures that integrate multiple dimensions of resilience biology. Such signatures may include non-coding RNA profiles that regulate both epigenetic stability and immune tolerance, quantitative measures of senescence-associated secretory factors that reflect the accumulation of dysfunctional cells, and longitudinal tracking of inflammatory mediators that signal erosion of adaptive capacity. A multidimensional biomarker framework would not only allow prediction of autoimmune risk but could also serve as a metric for evaluating the effectiveness of resilience-enhancing interventions. These integrated biomarkers may help identify individuals at high risk earlier and enable more personalized therapeutic strategies.

Current therapies for autoimmune diseases have historically relied on broad immunosuppressive agents that attenuate global immune activation. In recent years, however, targeted approaches including biologic and small-molecule disease-modifying antirheumatic drugs (DMARDs) have transformed clinical management by selectively blocking key cytokines, receptors, or intracellular signaling pathways (for example, anti–TNF, IL-6R, and JAK inhibitors) (190 –194). While these advances limit the off-target effects of traditional immunosuppression, they remain primarily directed at dampening immune activation rather than restoring the underlying resilience pathways that sustain tolerance and repair. A future therapeutic paradigm should therefore aim to complement these targeted agents with interventions that enhance resilience itself (Supplementary Table 2). Potential strategies include the use of senolytic drugs to selectively eliminate senescent cells and reduce their pro-inflammatory secretory output. Examples of senolytic agents include the BCL-2 family inhibitor navitoclax (ABT-263), the combination of dasatinib plus quercetin that targets senescent endothelial and adipocyte progenitor cells, and the flavonoid fisetin, which promotes apoptosis of senescent immune and stromal cells (195 –203). Additional classes under investigation include HSP90 inhibitors (such as ganetespib) and FOXO4–p53 interaction disruptors (such as FOXO4-DRI peptides), both of which restore tissue repair capacity and reduce the senescence-associated secretory phenotype in preclinical models (204 –206).

Supplementation or pharmacological activation of nicotinamide adenine dinucleotide can further restore metabolic and mitochondrial function, while epigenetic modulators stabilize DNA methylation and histone landscapes in autoreactive immune cells. Nicotinamide adenine dinucleotide (NAD⁺) is a central coenzyme in redox reactions and a key regulator of cellular metabolism, mitochondrial function, and DNA repair (44, 207, 208). Age related declines in NAD⁺ levels contribute to impaired sirtuin activity, mitochondrial dysfunction, and increased inflammatory signaling, which are hallmarks of resilience erosion (209 –212). NAD targeted therapies aim to replenish intracellular NAD⁺ pools or enhance their biosynthetic pathways, thereby restoring metabolic resilience (213 –215). Strategies under investigation include supplementation with NAD⁺ precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), inhibition of NAD⁺ consuming enzymes such as CD38, and activation of sirtuins that rely on NAD⁺ as a substrate (216). Preclinical studies demonstrate that these interventions can reduce inflammaging, improve mitochondrial biogenesis, and reestablish immune tolerance, highlighting their potential as resilience enhancing approaches in age associated autoimmunity (212, 217 –221).

Emerging RNA-based therapies that target microRNAs or long non-coding RNAs may also provide unprecedented precision in re-establishing tolerance while sparing global immune suppression. For example, anti-miR-21 and anti–miR-155 oligonucleotides have demonstrated immunoregulatory effects in preclinical autoimmune models by dampening pathogenic Th17 and B-cell activation, while GAS5-mimetic lncRNA constructs are being developed to restore regulatory T-cell homeostasis and immune tolerance (105, 222 –224). By directly supporting resilience pathways, these interventions may help delay autoimmune onset, reduce disease severity, and potentially extend healthspan.

To translate these concepts into clinical impact, new approaches to human research are required. Longitudinal cohort studies that track individuals from early adulthood through late life, with systematic measurement of resilience markers alongside autoimmune activity, will be essential to map causal trajectories. Single-cell multiomics, integrating transcriptomic, epigenomic, proteomic, and metabolic data at the level of individual immune cells (225 –228), will provide unprecedented resolution of the cross-talk between resilience pathways and autoreactive potential. Spatial multiomics could further reveal how resilience erosion interacts with local tissue environments, clarifying why certain organs such as the pancreas, central nervous system, and joints exhibit particular vulnerability. These approaches will also facilitate the identification of therapeutic targets and the refinement of personalized interventions.

Autoimmunity can emerge through heterogeneous mechanisms across the human lifespan. However, the conceptual framework advanced here focuses primarily on late-onset forms that are mechanistically linked to the progressive erosion of biological resilience. These conditions are interpreted as emergent phenomena arising from cumulative failures across molecular, cellular, and systemic adaptive networks rather than from discrete congenital or developmental defects in immune regulation. Delineating this scope refines the mechanistic precision of our model and situates autoimmunity within the broader continuum of age-associated physiological decline. Within this defined context, autoimmune disease may be viewed as an early sentinel of resilience collapse, reflecting the heightened sensitivity of the immune system to perturbations in homeostatic control. As resilience pathways that normally sustain repair, tolerance, and adaptive recalibration deteriorate, immune dysregulation manifests as one of the earliest measurable indicators of systemic instability. In this view, autoimmunity represents not merely a discrete breakdown of immune tolerance but a systems-level indicator of diminishing resilience capacity. As the immune system is uniquely positioned at the intersection of molecular surveillance, cellular adaptation, and systemic integration, autoimmune activation functions as an early barometer of resilience failure. Molecular surveillance refers to the continuous monitoring of molecular integrity within cells and tissues, including the detection and repair of DNA damage, removal of misfolded or oxidized proteins, sensing of metabolic stress, and recognition of pathogen- or damage-associated molecular patterns by innate immune receptors. Aberrant self-recognition thus represents less a discrete immunological accident than a measurable tipping point in the broader capacity of the organism to withstand stress, repair injury, and recalibrate after perturbation.

This reframing has profound implications. First, it positions autoimmunity as a leading indicator of healthspan erosion, much like arrhythmias can signal cardiac instability before heart failure. Second, it highlights the value of autoimmune phenotypes as a research window into resilience dynamics, providing a natural model through which to dissect the interplay of stress response, repair capacity, and adaptive limits. Finally, it redirects therapeutic goals: rather than merely quelling inflammatory damage, interventions should be evaluated for their capacity to rebuild resilience architecture. This entails restoring feedback control, reinforcing tolerance checkpoints, and re-establishing systemic adaptability.

In this perspective, autoimmunity is not only a clinical challenge but also a conceptual gateway to reimagining preventive medicine. Interpreting autoimmune manifestations as early-system sentinel events could enable earlier recognition of resilience decline, support more targeted therapeutic intervention, and ultimately improve functional longevity.

Although framing autoimmunity as a sentinel of resilience collapse is conceptually integrative, it may oversimplify the diverse etiologies and age distributions of autoimmune diseases. Environmental exposures, hormonal influences, and genetic predispositions contribute substantially and may intersect with, but not be wholly explained by, resilience biology. Future research should therefore delineate disease- and age-specific resilience signatures to avoid overgeneralization of this model.